MT2023-33 A Phase II Study of Reduced Dose Post Transplantation; Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Cyclophosphamide is a chemotherapy (chemo) drug often given after a transplant to prevent graft-versus-host disease (GvHD). We are doing this study to see if a lower dose of cyclophosphamide after transplant is as safe and works just as well. This study does not include any new or untested drugs. The drugs and procedures in this study are standard for people who receive a transplant.
• between 18 and 66 years old
• receiving an unrelated Donor Peripheral Blood Stem Cell Transplantation
• willing to comply with all study procedures and availability for the duration of the study
• see link to clinicaltrials.gov for complete Inclusion Criteria
• prior allogeneic transplant
• autologous transplant within the past 3 months
• women who are pregnant or breast feeding
• HIV+ with persistently positive viral load
• study staff will review
Drug: Busulfan, Drug: Cyclophosphamide, Drug: Fludarabine, Drug: Melphalan, Drug: Mesna, Drug: Mycophenolate Mofetil, Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT), Other: Patient Reported Outcomes, Drug: Post-Transplant Cyclophosphamide, Drug: Tacrolimus, Radiation: Total-body irradiation
Cancer
Clinics and Surgery Center (CSC), Acute Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Myelodysplastic Syndromes